Key result
Second Moderna COVID-19 vaccine dose linked to rapidly resolving myocarditis presenting as STEMI.
Case Report (n=1)
Highlights a rare case of COVID-19 mRNA vaccine-associated myocarditis presenting as STEMI in a 48-year-old male, suggesting prior viral myocarditis might be a predisposing factor.
Answers are grounded in this paper and cite their sources.
Myocarditis should be considered in recent mRNA vaccine recipients with STEMI-like presentations; this case leaves open incidence and predisposing factors.
Myocarditis has been recognized as a rare complication of coronavirus disease 2019 (COVID-19) mRNA vaccinations. Young adult and adolescent males < 30 years of age are the most commonly affected group, with decreased incidence with older age. This is a case of a 48-year-old male who presented with chest pain and EKG findings of STEMI shortly after receiving the second dose of the Moderna COVID-19 mRNA vaccine. Emergent left heart catheterization revealed normal coronaries. Subsequently, the patient had rapid resolution of his symptoms and improvement in serum markers. The exact etiology factors to this new and rare phenomenon are yet to be fully understood. This patient did have a history of previous viral myocarditis 7 years ago; however, it remains unclear if this could be a predisposing factor to the development of mRNA vaccine-associated myocarditis.
No takes yet. Share an insight, caveat, or question.
Dlewati et al. (2022) conducted a case report in Myocarditis presenting as STEMI (n=1). Moderna COVID-19 mRNA vaccine was evaluated. A 48-year-old male developed myocarditis presenting as STEMI shortly after receiving the second dose of the Moderna COVID-19 mRNA vaccine, followed by rapid resolution of symptoms.
Synapse has enriched 10 related papers. Consider them for comparative context: